Mr. Thomas Smeenk reports

HEMOSTEMIX WELCOMES SHAUNE HARDING, OSTJ, RN AS DIRECTOR OF PATIENT CARE & CLINICAL OPERATIONS

Hemostemix Inc. has appointed Shaune Harding, OStJ, non-practising RN, as director of patient care and clinical operations. In this senior clinical role, Ms. Harding will oversee:

• On-boarding of all new patients entering Hemostemix treatment programs;
• Comprehensive medical record review and HIPAA-compliant transfer of patient records to the treating physician team;
• Patient health journey mapping from initial assessment through treatment and multiyear follow-up;
• Continuous patient data monitoring, including heart rate, activity, exercise and sleep metrics captured through approved wearable devices such as Fitbit Sense 2;
• Monthly follow-up meetings to support goal setting, health care journey adherence and improvements in functional status;
• Adverse event monitoring, documentation and reporting, including:
  • Real-time tracking of patient-reported issues;
  • Immediate escalation protocols to the treating physician;
  • Formal reporting to Hemostemix's clinical operations team and regulators;
  • Ensuring compliance with regulatory, clinical and safety obligations.

Ms. Harding brings more than three decades of patient hands-on clinical and management experience to her role, which will be leveraged to advance Hemostemix's personalized care experience in the Bahamas, Florida and Canada. This integrated role strengthens Hemostemix's hands-on, patient-centric health care model. It ensures long-term continuity of care for all who are treated with VesCell. Equally important, it enables patient data capture, which will be used to advance regulatory approval of ACP-01.

"I've known Shaune since 1967," said Thomas Smeenk, president and chief executive officer of Hemostemix. "Shaune has always been one of the best-hearted friends anyone could have. Hemostemix's patients are going to love working with her as she will help them get assessed, on board, treated and followed up monthly. Shaune is the perfect person to guide patients throughout their health journey, and I'm thrilled to welcome her to head our patient care team," Mr. Smeenk said.

About Hemostemix Inc.

Hemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum technology pioneer award, the company has developed, has patented, is scaling and is selling autologous (patient's own) blood-based stem cell therapy, VesCell (ACP-01). Hemostemix has completed seven clinical studies of 318 subjects and published its results in 11 peer-reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non-ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure and angina. Hemostemix completed its phase 2 clinical trial for chronic limb-threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared with a five-year mortality rate of 50 per cent in the CLTI patient population, University of British Columbia and University of Toronto reported to the 41st meeting of vascular surgeons: 0 per cent mortality, cessation of pain and wound healing in 83 per cent of patients followed for up to 4.5 years as a midpoint result.

We seek Safe Harbor.